GlassScriptPhysician profile
Benjamin T Feeney
NPI 1992020754
$8,653.14
in general payments reported to CMS, 2019-2025
14 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.29 · 2021: $91.88 · 2022: $123 · 2023: $136 · 2024: $7,086 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $2,366 · Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $2,365.83 |
| Food and Beverage | $558.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,726.97 | 2024-2025 | |
| Alphatec Spine, INC | $561.20 | 2024 | Other - Miscellaneous |
| Astrazeneca Pharmaceuticals LP | $113.51 | 2022-2023 | Imfinzi, Tagrisso |
| Avanos Medical | $35.80 | 2023 | On-Q* Pump and Accessories |
| Musculoskeletal Transplant Foundation INC. | $32.06 | 2023 | |
| Daiichi Sankyo INC. | $27.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $27.25 | 2021 | |
| Genzyme Corporation | $24.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2021 | |
| Merck Sharp & Dohme LLC | $19.54 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.63 | 2022 | |
| Novo Nordisk INC | $14.29 | 2019 | |
| Incyte Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Feeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.